small cell lung cancer
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
Small Cell Lung Cancer Study Uncovers Disease-Associated Germline Mutations
The study, which showed that the disease may not only result from tobacco exposure as previously thought, could lay the groundwork for targeted therapies.
The transcription-based subtypes could differentiate which SCLC patients respond to treatments, such as immune checkpoint inhibitors and PARP inhibitors.
Blood-Based MicroRNA Signatures Can Distinguish Individuals With Lung Cancer
A retrospective cohort study uncovered microRNA signatures that could tell lung cancer patients apart from others, including patients with other, non-tumor lung conditions.
The firm said that its cell-free DNA assay has shown a high positive predictive value in preliminary clinical studies involving stage IV colorectal cancer patients.